4th Paediatric FH Virtual Symposium

Welcome the resceduled 4th EAS Paediatric Familial Hypercholesterolemia Satellite Symposium, which will be a virtual meeting on Saturday May 29th, 2021 as part of the virtual EAS congress in Helsinki.

Note: Times are presented in Helsinki time (CET +1 h)

Organized by: Dr Nathalie Brun, Jeanine Roeters van Lennep, Steve Humphries and Katriina Aalto-Setala

11.00-11.05: Welcome and dedication to Gaby Hanauer-Mader

Steve Humphries

11.05-12.00: Plenary Session

Katriina Aalto-Setala (Finland), Uma Ramaswami (UK)

  1. Characteristics of Children with FH in the FHSC database – Antonio Vallejo-Vaz (UK)
  2. Safety and Efficacy of use of Evolocumab in Children – Albert Wiegman (Holland)

15 minute Break

12.15-13.45: Three Parallel sessions of up to 90 minutes 

Topic 1 - Safety and efficacy of lipid lowering treatments
Chair Jeanine Roeters van Lennep and TBC

  • How big is the risk of fetal anomalies due to statin use in pregnancy? Meeike Kusters (Holland)
  • FH and Pregnancy – results of a survey - Kirsten Holven (Norway)
  • Liver transplantation in HOZ FH – Is this only a last resort treatment? Jeanine Roeters van Lennep (Holland)
  • Pediatric HoFH trial with lomitapide and recent data – Luis Masana (Spain)
  • Q & A session (30 mins).


Topic 2 - Update on FH Genetics
Chair Steve Humphries and Alpo Vuorio (Finland)

  1. Genetics of FH: Founder effects in Nordic countries - Martin Bogsrud (Norway)
  2. Mutation spectrum and genotype-phenotype analysis in children with FH in the IAS FH Pediatric Register - Marta Futema (UK)
  3. Genetics of LAL-D : A clinically useful differential diagnosis of FH – Steve Humphries (UK)
  4. New genes causing FH – update from the UK 100,000 genome project – Antoine Rimbert (France)
  5. How to handle the findings of a VUS in an index case – In silico predictions, AMCG criteria and in vitro Assays – Mafalda Bourbon (Portugal) and Tomas Freiberger (Czech Republic)
  6. Q & A session (30 mins)


Topic 3 - Universal Screening for FH in childhood
Chair Dr Nathalie Brun and Petri Kovanen (Finland)

  1. What do Patients value most about a diagnosis of FH and how this can be used as part of evidence of clinical utility - Jules Payne (UK)
  2. The Russian Experience – Marat Ezhov (Russia)
  3. The Bavaria Project – Heribert Schunkert (Germany)
  4. The Berlin and Mecklenburg experience - Elizabeth Steinhagen-Thiessen (Germany)
  5. The Australian experience - Gerald Watts (Australia)
  6. Q & A session (30 mins)

Session Break

15.00-16.25 : Plenary Session and wrap-up

Chair Albert Wiegman and  Harri Niinikoski (Finland)

  1. Early Exposure to high LDL-C and future CHD risk – trajectory analysis - Andrew Moran (USA)
  2. Are statin treated FH children at higher risk of T2D? – Justin Zachariah (USA)
  3. Q &A 15 mins
  4. Presentation and discussion of “Clinical Scenario” survey (Michal Vrablik (Czech Republic) 20 mins)


16.30 End of Meeting - Thanks and Presentation of voting for topics for 2022

Steve Humphries